Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters.

Q1 Medicine CNS Oncology Pub Date : 2020-06-01 Epub Date: 2020-06-30 DOI:10.2217/cns-2020-0007

Antonio Dono, Anthony Patrizz, Ryan M McCormack, Nagireddy Putluri, Bhanu P Ganesh, Balveen Kaur, Louise D McCullough, Leomar Y Ballester, Yoshua Esquenazi

{"title":"Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters.","authors":"Antonio Dono, Anthony Patrizz, Ryan M McCormack, Nagireddy Putluri, Bhanu P Ganesh, Balveen Kaur, Louise D McCullough, Leomar Y Ballester, Yoshua Esquenazi","doi":"10.2217/cns-2020-0007","DOIUrl":null,"url":null,"abstract":"Aim: To explore fecal short-chain fatty acids and neurotransmitter alterations in a mouse-glioma model and glioma patients. Methods: Liquid chromatography-mass spectrometry and 16S rRNA-sequencing from fecal samples were performed to measure metabolite levels and taxa abundance in mice/humans. Mice underwent GL261 implantation with/without temozolomide. Glioma patients were compared with healthy controls. Results: Glioma altered several short-chain fatty acids and neurotransmitter levels. Reduced 5-hydroxyindoleaceic acid and norepinephrine levels were seen in mice and humans. Interestingly, temozolomide treatment abrogates the effects of glioma on fecal metabolites. Conclusion: Our findings demonstrate the interplay between glioma and the gut-brain axis. Further work is required to identify pathways within the gut-brain axis by which glioma influences and promotes the modulation of fecal metabolites and microbiome.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"9 2","pages":"CNS57"},"PeriodicalIF":0.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0007","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2020-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/6/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 18

Abstract

Aim: To explore fecal short-chain fatty acids and neurotransmitter alterations in a mouse-glioma model and glioma patients. Methods: Liquid chromatography-mass spectrometry and 16S rRNA-sequencing from fecal samples were performed to measure metabolite levels and taxa abundance in mice/humans. Mice underwent GL261 implantation with/without temozolomide. Glioma patients were compared with healthy controls. Results: Glioma altered several short-chain fatty acids and neurotransmitter levels. Reduced 5-hydroxyindoleaceic acid and norepinephrine levels were seen in mice and humans. Interestingly, temozolomide treatment abrogates the effects of glioma on fecal metabolites. Conclusion: Our findings demonstrate the interplay between glioma and the gut-brain axis. Further work is required to identify pathways within the gut-brain axis by which glioma influences and promotes the modulation of fecal metabolites and microbiome.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胶质瘤诱导粪便短链脂肪酸和神经递质的改变。

目的:探讨小鼠胶质瘤模型和胶质瘤患者粪便中短链脂肪酸和神经递质的变化。方法:采用液相色谱-质谱法和16S rrna测序法测定小鼠/人粪便中代谢物水平和类群丰度。替莫唑胺加/不加GL261植入小鼠。将胶质瘤患者与健康对照组进行比较。结果:胶质瘤改变了几种短链脂肪酸和神经递质水平。小鼠和人体内的5-羟基吲哚乙酸和去甲肾上腺素水平均降低。有趣的是，替莫唑胺治疗消除了胶质瘤对粪便代谢物的影响。结论:我们的研究结果表明胶质瘤与肠-脑轴之间存在相互作用。需要进一步的工作来确定肠-脑轴内胶质瘤影响和促进粪便代谢物和微生物组调节的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊